What did @indiatoday actually say?
The video covers Anaya Bangar's gender transition through hormone replacement therapy, describing it as causing her to lose strength while gaining happiness over a 10-month period. The reporter also quotes Anaya directly: her testosterone levels are "down to 0.5 nmol/L, the lowest it can be." The piece frames HRT as a trade-off, and raises a genuine policy contradiction: Indian law prohibits transition before adulthood, yet sports bodies require pre-pubertal transition for women's competition eligibility.
The framing is mostly sympathetic journalism rather than medical instruction, which matters for how we assess it. The reporter does briefly define HRT as "a medical treatment often used to address hormonal imbalances particularly during menopause," which is an incomplete and somewhat misleading starting point for a story about gender-affirming care.
Does the science back this up?
The core claim, that HRT causes meaningful strength reduction in trans women, is supported by the literature. The direction is right. But the timeline and degree of change are more complex than a 10-month window suggests.
Wiik et al. (2020, Journal of Clinical Endocrinology and Metabolism) found that after two years of feminizing HRT, trans women showed significant reductions in muscle mass and strength, but still retained some measurable advantage over cisgender women in certain metrics. Harper et al. (2021, British Journal of Sports Medicine) tracked trans women runners and found performance gaps narrowed but did not fully close within two years of HRT. The 0.5 nmol/L testosterone figure Anaya cites is consistent with suppression targets used in clinical protocols, typically below 1.73 nmol/L per Endocrine Society guidelines. That part checks out. What the video does not address is that bone density, lung capacity, and prior muscle fiber development do not reverse as quickly as testosterone levels drop. Strength loss is real. Full physiological parity with cisgender women is a longer and more contested story.
What did they get wrong (or right)?
The menopause framing is a real problem. Defining HRT primarily as a menopause treatment before pivoting to gender-affirming care is not just imprecise, it implies the two are essentially the same intervention. They are not. Menopausal HRT typically involves estrogen supplementation, sometimes with progesterone. Gender-affirming HRT for trans women involves estrogen plus antiandrogens or testosterone suppression, and the goals, dosing, monitoring, and psychological context are distinct. The Endocrine Society and WPATH both treat these as separate clinical categories for good reason.
What they got right: the policy contradiction Anaya raises is accurate and documented. India's Transgender Persons (Protection of Rights) Act, 2019 restricts transition-related procedures for minors, while sports eligibility frameworks increasingly demand evidence of transition before or during puberty. That is a real structural conflict, not an opinion. The video deserves credit for naming it plainly.
What should you actually know?
If you are considering or currently on gender-affirming HRT, the science on physical changes is real but gradual. Testosterone suppression to levels like 0.5 nmol/L does reduce circulating androgen effects, including some muscle mass and strength over time. But "10 months" is not a complete picture. Most studies follow patients over two to four years minimum, and individual variation is significant.
- Suppression of testosterone does not immediately erase puberty-acquired physical traits. Changes to bone structure, height, and certain strength metrics are either permanent or very slow to shift.
- Monitoring during HRT matters. Estrogen therapy carries risks including thromboembolic events. Seal et al. (2012, Clinical Endocrinology) documented these risks in trans women on oral estrogen specifically.
- The sports eligibility debate is not settled science. The IOC moved away from testosterone-only thresholds in its 2021 framework, acknowledging the evidence base is insufficient to make firm universal rules.
- If you are in India and seeking gender-affirming care, WPATH-trained providers and endocrinologists familiar with the Endocrine Society's guidelines are your best starting point, not social media.
Bottom line: is this video worth sharing?
As a human interest piece about a real person navigating real institutional gaps, it has value. As medical education about HRT, it falls short. The menopause definition is sloppy. The timeline for physical changes is compressed in a way that overstates how fast HRT works. The policy section is the strongest part of the video and holds up to scrutiny. Share it for the advocacy angle. Do not use it to understand how gender-affirming HRT actually works in the body.